65,437 trials
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c at Week 24 — -0.69; 0.14 Percent — p=<0.001
Factor X Deficiency
Primary: The Number of Participants With Excellent Reduction in Bleeding When Given FACTOR X as Routine Prophylaxis Over 6 Months — 9 Participants
Alcohol Abuse · Alcohol Dependence
Primary: Number of Participants With Hazardous Drinking — 292; 309; 201; 223 Participants
Opioid-Induced Constipation
Primary: Number of Laxations Per Subject Within 24 Hours of Dosing Per Week. — 1.7; 2.4; 2.6; 3.4 Number of laxations
Depression
Primary: Depressive Symptoms — 9.736; 11.785; 8.880; 12.300 units on a scale — p=<.05
Schizophrenia
Primary: Change From Baseline in Cognition on MCCB — 45.0; 45.2; 45.8 T-scores
Glioblastoma · Gliomas
Primary: 12 Month Overall Survival of Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concurrent Temozolomide and Radiotherapy Followed by Dose Dense or…
Panic Disorder
Primary: Panic Disorder Severity Scale (PDSS) — 13.30; 13.37; 7.98; 8.32 units on a scale
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c at Week 24 — -0.84; -0.07 Percent — p=<0.001
Cancer · Hematologic Malignancies · Multiple Myeloma
Primary: Time to First On-study Skeletal Related Event — 730.0; 695.0 days — p=0.010
Burn
Primary: Pain During Dressing Change — 6.36; 6.94 units on a scale
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Response Rate — 29 percentage of participants
Nasal Obstruction
Primary: Improvement in NOSE Score — 54.8 units on a scale — p=<0.0001
Short-term Insomnia
Primary: Total Sleep Time — 382.9; 339.2; 256.2 minutes
Hypoglycemia
Primary: Change in Baroreflex Sensitivity — 2.3; -1.6 ms/mmHg